Logo

Alife Health Named to the 2022 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Alife recognized for achievements in artificial intelligence tools for the reproductive healthcare field

San Francisco /May 17th, 2022

CB Insights today named Alife Health to its annual AI 100 ranking, showcasing the 100 most promising private artificial intelligence companies in the world.

"This is the sixth year that CB Insights has recognized the most promising private artificial intelligence companies with the AI 100. This year's cohort spans 13 industries, working on everything from recycling plastic waste to improving hearing aids," said Brian Lee, SVP of CB Insights’ Intelligence Unit. "Last year's AI 100 companies had a remarkable run, raising more than $6 billion, including 20 mega-rounds worth more than $100 million each. We’re excited to watch the companies on this year’s list continue to grow and create products and services that meaningfully impact the world around them.”

Utilizing the CB Insights platform, the research team picked 100 private market vendors from a pool of over 7,000 companies, including applicants and nominees. They were chosen based on factors including R&D activity, proprietary Mosaic scores, market potential, business relationships, investor profile, news sentiment analysis, competitive landscape, team strength, and tech novelty. The research team also reviewed thousands of Analyst Briefings submitted by applicants.

Alife is a fertility technology company building a modern operating system for IVF clinicians. Alife’s technology empowers clinical decision-making with personalized, data-driven insights to help clinicians maximize each patient’s chances of success while lowering costs and barriers to access.

The AI company is differentiated in its product approach, scientific rigor, and access to data. The company has built a consortium of partnerships with the largest clinics and most renowned physicians to build the largest and most diverse dataset in the world. With Alife, clinicians can modernize and personalize the IVF process with cutting-edge artificial intelligence technology that improves outcomes and care for all.

Quick facts on the 2022 AI 100:

  • Equity funding and deals: Since 2017, the 2022 AI 100 cohort has raised $12 billion+ from 650 investors, across 300+ equity deals.
  • Unicorns: There are 16 companies with $1 billion+ valuations on the list.
  • Geographic distributions: Seventy-three of the selected companies are headquartered in the US. Eight of the winners are based in the UK, followed by five in Canada. Other countries represented in this year’s list include India, Sweden, China, and Germany.

About Alife Health

Alife’s mission is to modernize and personalize the IVF process with cutting edge artificial intelligence technology to improve outcomes and care for all. The company has built a consortium of partnerships with the top clinics and most renowned physicians to bring significant clinical improvements to patients globally. Founded by Paxton Maeder-York in 2020, the company is based in San Francisco and backed by top tier venture capital investors including Lux Capital, Union Square Ventures, and Maveron.

PRESS CONTACT: Jamie Gray, press@alifehealth.com, 310-699-3163